Mendoza Tito R, Dueck Amylou C, Bennett Antonia V, Mitchell Sandra A, Reeve Bryce B, Atkinson Thomas M, Li Yuelin, Castro Kathleen M, Denicoff Andrea, Rogak Lauren J, Piekarz Richard L, Cleeland Charles S, Sloan Jeff A, Schrag Deborah, Basch Ethan
1 Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2 Mayo Clinic, Scottsdale, AZ, USA.
Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.
The US National Cancer Institute recently developed the PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events). PRO-CTCAE is a library of questions for clinical trial participants to self-report symptomatic adverse events (e.g. nausea). The objective of this study is to inform evidence-based selection of a recall period when PRO-CTCAE is included in a trial. We evaluated differences between 1-, 2-, 3-, and 4-week recall periods, using daily reporting as the reference.
English-speaking patients with cancer receiving chemotherapy and/or radiotherapy were enrolled at four US cancer centers and affiliated community clinics. Participants completed 27 PRO-CTCAE items electronically daily for 28 days, and then weekly over 4 weeks, using 1-, 2-, 3-, and 4-week recall periods. For each recall period, mean differences, effect sizes, and intraclass correlation coefficients were calculated to evaluate agreement between the maximum of daily ratings and the corresponding ratings obtained using longer recall periods (e.g. maximum of daily scores over 7 days vs 1-week recall). Analyses were repeated using the average of daily scores within each recall period rather than the maximum of daily scores.
A total of 127 subjects completed questionnaires (57% male; median age: 57). The median of the 27 mean differences in scores on the PRO-CTCAE 5-point response scale comparing the maximum daily versus the longer recall period (and corresponding effect size) was -0.20 (-0.20) for 1-week recall, -0.36 (-0.31) for 2-week recall, -0.45 (-0.39) for 3-week recall, and -0.47 (-0.40) for 4-week recall. The median intraclass correlation across 27 items between the maximum of daily ratings and the corresponding longer recall ratings for 1-week recall was 0.70 (range: 0.54-0.82), for 2-week recall was 0.74 (range: 0.58-0.83), for 3-week recall was 0.72 (range: 0.61-0.84), and for 4-week recall was 0.72 (range: 0.64-0.86). Similar results were observed for all analyses using the average of daily scores rather than the maximum of daily scores.
A 1-week recall corresponds best to daily reporting. Although intraclass correlations remain stable over time, there are small but progressively larger differences between daily and longer recall periods at 2, 3, and 4 weeks, respectively. The preferred recall period for the PRO-CTCAE is the past 7 days, although investigators may opt for recall periods of 2, 3, or 4 weeks with an understanding that there may be some information loss.
美国国立癌症研究所最近开发了PRO-CTCAE(患者报告的不良事件通用术语标准版本)。PRO-CTCAE是一个供临床试验参与者自我报告症状性不良事件(如恶心)的问题库。本研究的目的是为在试验中纳入PRO-CTCAE时基于证据选择回忆期提供信息。我们以每日报告作为参考,评估了1周、2周、3周和4周回忆期之间的差异。
在美国的四个癌症中心及其附属社区诊所招募了接受化疗和/或放疗的讲英语的癌症患者。参与者在28天内每天以电子方式完成27项PRO-CTCAE项目,然后在接下来的4周内每周完成一次,分别采用1周、2周、3周和4周的回忆期。对于每个回忆期,计算平均差异、效应大小和组内相关系数,以评估每日评分的最大值与使用较长回忆期获得的相应评分之间的一致性(例如,7天内每日评分的最大值与1周回忆期的评分)。分析重复使用每个回忆期内每日评分的平均值而非每日评分的最大值。
共有127名受试者完成了问卷调查(57%为男性;中位年龄:57岁)。在PRO-CTCAE的5分制反应量表上,比较每日评分最大值与较长回忆期(及相应效应大小)时,27个平均差异的中位数在1周回忆期为-0.20(-0.20),2周回忆期为-0.36(-0.31),3周回忆期为-0.45(-0.39),4周回忆期为-0.47(-0.40)。1周回忆期的每日评分最大值与相应较长回忆期评分之间,27个项目的组内相关系数中位数为0.70(范围:0.54 - 0.82),2周回忆期为0.74(范围:0.58 - 0.83),3周回忆期为0.72(范围:0.61 - 0.84),4周回忆期为0.72(范围:0.64 - 0.86)。使用每日评分平均值而非每日评分最大值进行的所有分析均观察到类似结果。
1周回忆期与每日报告最为匹配。尽管组内相关系数随时间保持稳定,但在2周、3周和4周时,每日与较长回忆期之间分别存在虽小但逐渐增大的差异。PRO-CTCAE的首选回忆期是过去7天,不过研究者在了解可能存在一些信息丢失的情况下,可选择2周、3周或4周的回忆期。